ENITEC

European Network of Individual Treatment in Endometrial Cancer

 

ENITEC

ENITEC is a pan-European academic Network for Translational Researchers in Gynaecological Oncology, who gather together to share their expertise in uterine cancer research, with a particular focus on integration of molecular studies to improve and individualize patient care.

The ultimate goal of the Network is to improve and individualize treatment of women with uterine cancers by integrating the best science in state of the art clinical care, and enabling every patient to access benefits from translational research. ENITEC was founded in 2012 and has grown ever since.

 

ENITEC members

Researchers within the network have widely varying backgrounds, including clinical (gynaecology, pathology, radiology), molecular biologists and pharmacists to name a few.

All ENITEC members are encouraged to become ESGO member.

Since ENITECs foundation, over 130 researchers from research groups all across Europe, illustrated in the map, have become involved.

 

 

Activities

Annual Meeting

June 7-8, 2018 
Amsterdam, the Netherlands

 

ENITEC organises an annual meeting where all ENITEC-associated researchers are invited to join.

The venue rotates annually. The 2018 meeting will be held in Amsterdam, the Netherlands; June 7-8. At the meeting, the network will discuss updates on the ongoing collaborative studies and evaluate the proposal of new projects.

 

Publications

Publications of the research carried out under the umbrella of the ENITEC network are presented in our google scholar profile, as well as other publications, i.e. PhD theses from researchers connected to the network.

Interested to add publications to the ENITEC google scholar profile, contact the ENITEC chair.

Find out more on the ENITEC published research on scholar.google.com.

Clinical Studies

The ENITEC Network provides its members the opportunity to join a TAKEDA sponsored PHASE-II clinical trial.

This joint initiative of ENITEC-EUTROC-TAKEDA, involves treatment of women with advanced, recurrent, or persistent endometrial Cancer with combination of MLN0128 and/or weekly Paclitaxel .

260 patients from approximately 60 centres across North America, Europe and Asia Pacific will be randomized into the study.

Tissue material (baseline and follow up biopsies) will be used to generate research material (frozen and fixed tissue) available from the patient arms.

This material will be available to EUTROC-ENITEC investigators from TAKEDA to investigate important translational science questions.

Clinicaltrials.gov identifier: NCT02725268

 

Momatec2 is a clinical study that ENITEC members can participate in. This initiative from Bergen, Norway, is a phase 4 study where the hormone receptors ER and PR are used to better risk stratify presumed low and intermediate risk stage 1 endometrial cancer patients, in order to optimise the percentage of patients needing to undergo lymphadenectomy.

Clinicaltrials.gov identifier: NCT02543710

ENITEC Leadership

Henrica Werner

Chair: HMJ (Erica) Werner

Haukeland university hospital/University of Bergen, Norway

Henrica.werner@uib.no

 

Erica Werner works as fellow gynaecological oncology at Haukeland university hospital in Bergen (N) and is associate professor at the university of Bergen.

She graduated from Maastricht University (NL) and after a dual Dutch/UK training programme she moved to Norway where she started practising as gynaecologist in 2009.

She obtained her PhD on‘clinical and molecular markers in endometrial cancer’ in 2014. Her research profile is on translational research in gynaecological cancerand she is PI for the Momatec2 study.

In 2017 she became associate professor. Starting its foundation she has been active in ENITEC and was chair elect from 2015-2017.

Hanny Pijnenborg | TweeSteden ziekenhuis 2013

Chair-elect: JMA (Johanna) Pijnenborg

Radboud UMC Nijmegen, the Netherlands

Hanny.ma.pijnenborg@radboudumc.nl

 

Johanna (Hanny) MA Pijnenborg, is gynaecological oncologist at the Radboud University Medical Center Nijmegen (NL). She defended her thesis “The Predictive value of molecular markers for recurrent endometrial carcinoma” in 2005.

She has done her fellow-ship gynecological oncology at the Radboud University Medical Center in 2009-2010. In 2016 she started as gynaecological oncologist in Nijmegen where she initiated the endometrial research group in 2010.

Her main research focus is translational research in endometrial cancer.

In 2012 she joined ENITEC, and since then is a very active member of the ENITEC group with several ongoing collaborative studies within the network.

frederic

Past chair: F (Frederic) Amant

Frederic.amant@uzleuven.be

 

Frédéric Amant, MD, PhD (1967), received his medical degree from the University of Leuven (KU Leuven). He heads the Center for Gynaecologic Oncology at the Antoni van Leeuwenhoek - Netherlands Cancer Institute and Academic Medical Center in Amsterdam.

At KU Leuven he heads the scientific section of this specialty.

He is professor at the KU Leuven in Belgium and at the University of Amsterdam in the Netherlands.Frédéric Amant heads the International Network on 'Cancer, Infertility and Pregnancy' (INCIP) of the European Society of Gynecologic Oncology (ESGO). Together with Helga Salvesen, he co-founded ENITEC.

Upcoming events

banner web 194x170

Surgery Course

Ovarian Cancer Surgery Course
Mar 22-24, 2018, Hamburg, Germany

Apply Now!

Read More

ESGO 2018 294X170

Conference

ESGO State of the Art 
Oct 4-6, 2018, Lyon, France

Save the Date!

Read More

athens 294x174

Congress

ESGO 21st CONGRESS
Nov 2-5, 2019, Athens, Greece

Save the Date!

Read More